Amneal Pharmaceuticals, Inc. $AMRX Holdings Increased by Odyssean LLC

Odyssean LLC lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 62.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,507 shares of the company’s stock after acquiring an additional 70,589 shares during the period. Odyssean LLC’s holdings in Amneal Pharmaceuticals were worth $3,177,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Westshore Wealth LLC bought a new stake in Amneal Pharmaceuticals during the third quarter worth approximately $13,833,000. Morgan Stanley lifted its position in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after purchasing an additional 1,069,400 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at $17,573,000. Finally, Penn Capital Management Company LLC acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at $12,655,000. 31.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the transaction, the executive vice president directly owned 35,171 shares of the company’s stock, valued at $611,975.40. This trade represents a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Kiely sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This trade represents a 19.21% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $17.44 on Friday. The company has a market capitalization of $5.57 billion, a PE ratio of 35.59 and a beta of 1.24. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a fifty day moving average of $17.76 and a 200-day moving average of $14.96. Amneal Pharmaceuticals, Inc. has a one year low of $9.44 and a one year high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on AMRX. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. UBS Group lifted their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $19.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.